Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

93 comunicati stampa

Guarda tutti i comunicati
28/05/2026
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/05/2026
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/05/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Mercato del lavoro
Industria
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
11/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
13/04/2026
Mercato del lavoro
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
09/03/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
20/02/2026
Mercato del lavoro
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/02/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
04/02/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0